Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NUVB vs CVAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVAC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

CVAC Overall Winner 6-Pillar Tally: NUVB 1 – 4 CVAC (1 Tie) Matrix Metrics: NUVB 4 – 6 CVAC

As of Nov 20, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. CVAC 60.2/100 BUY), CVAC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (573.0% vs. -61.2% operating margin) and revenue trajectory (-89.0% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile CVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NUVB vs CVAC
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87
CVAC NASDAQ Head-to-Head Winner
CureVac N.V. Ordinary Shares
Pharmaceutical Preparations
$4.66
-0.21% 1D
Market Cap $1.1B
TTM Revenue $71M
Forward P/E 5.2x
Beta / 30D Vol 1.20β · 62% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $4.64 · SMA50: $5.02

6-Pillar Scorecard Institutional Category Breakdown (NUVB 1 – 4 CVAC)

Columns: Metric · NUVB · CVAC
1. Valuation Multiples CVAC
Forward P/E N/M 5.2x
Trailing P/E N/M 7.0x
PEG Ratio N/M N/M
EV / Revenue 7.4x 14.9x
2. Growth & Scale NUVB
Revenue Growth (YoY) +242.6% -89.0%
Earnings Growth (YoY) +0.0% +24.0%
TTM Revenue (USD) $202M $71M
Market Cap $1.3B $1.1B
3. Profitability & Quality CVAC
Gross Margin 85.8% 93.3%
Operating Margin -61.2% 573.0%
Net Profit Margin -67.4% 182.1%
Return on Equity (ROE) -49.1% 40.2%
4. Balance Sheet & Cash Flow CVAC
Cash Generation (TTM) -$108M $194M EBITDA
Cash Flow Margin -53.6% N/A
Net Cash / Leverage $146M Net Debt (1.32x D/E) $5.65 Book/Sh · 40.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CVAC
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 65.2% (26th %ile) 63.4% (100th %ile)
Put/Call OI Skew 0.24x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NUVB (4) vs CVAC (6)
Institutional Metric NUVB CVAC Criterion Row Edge
Market Capitalization
Scale
$1.3B $1.1B Larger Scale NUVB
Trailing P/E Ratio
Valuation
N/M 7.0x Lower Multiple CVAC
Forward P/E Ratio
Valuation
N/M 5.2x Lower Multiple CVAC
Revenue Growth (YoY)
Growth
+242.6% -89.0% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-61.2% 573.0% Higher Margin CVAC
Net Profit Margin
Profitability
-67.4% 182.1% Higher Margin CVAC
Return on Equity (ROE)
Capital Efficiency
-49.1% 40.2% Higher ROE CVAC
52-Week Range Position
Momentum
2% ($4–$10) 67% ($2–$6) Stronger Trend CVAC
Beta / 30D Volatility
Risk Regime
1.52β · 55% Vol 1.20β · 62% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
61.0 / 100 (BUY) 60.2 / 100 (BUY) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$202M $71M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.8% 93.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · 14.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$108M ($146M Net Debt (1.32x D/E)) $194M EBITDA ($5.65 Book/Sh · 40.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NUVB +15.73 pp
NUVB: +5.78% · CVAC: -9.95%
3M Horizon NUVB +30.87 pp
NUVB: +20.14% · CVAC: -10.73%
6M Horizon NUVB +30.87 pp
NUVB: +20.14% · CVAC: -10.73%
1Y Horizon NUVB +30.87 pp
NUVB: +20.14% · CVAC: -10.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NUVB vs CVAC. Trailing 12-month operating profitability (NUVB -61.2% vs CVAC 573.0%) and valuation multiples (NUVB N/M vs CVAC 5.2x Forward P/E) are benchmarked directly in Pillar 4 below.

NUVB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$202M
Gross Margin85.8%
Op. Margin-61.2%
ROE / Fwd P/E-49.1% · N/M
CVAC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$71M
Gross Margin93.3%
Op. Margin573.0%
ROE / Fwd P/E40.2% · 5.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVAC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 63.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVAC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 573.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NUVB vs CVAC Key Questions & Quantitative Answers

As of Nov 20, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. CVAC 60.2/100 BUY), CVAC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (573.0% vs. -61.2% operating margin) and revenue trajectory (-89.0% vs. +242.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile CVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with CVAC at -89.0% YoY revenue growth and +24.0% YoY earnings growth on $71M TTM revenue (93.3% gross margin, 573.0% operating margin). On trailing 12-month operating scale, NUVB generates $202M in USD-normalized revenue versus $71M for CVAC. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVAC.

CVAC screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas CVAC trades at 5.2x Forward P/E, 7.0x Trailing P/E, N/M PEG, and 14.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus CVAC (40.2% ROE) capital efficiency.

In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, CVAC carries 63.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.20β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.